Country: Canada
Language: English
Source: Health Canada
OLMESARTAN MEDOXOMIL
APOTEX INC
C09CA08
OLMESARTAN MEDOXOMIL
10MG
TABLET
OLMESARTAN MEDOXOMIL 10MG
ORAL
100
Prescription
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Active ingredient group (AIG) number: 0152496004; AHFS:
APPROVED
2017-05-01
_APO-OLMESARTAN (Olmesartan medoxomil) _ _ _ _Page 1 of 33 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR APO-OLMESARTAN Olmesartan Medoxomil Tablets Tablets, 10 mg, Oral Angiotensin II AT 1 Receptor Blocker Apotex Standard APOTEX INC. 150 Signet Drive Toronto, Ontario M9L 1T9 Date of Initial Approval: MAY 01, 2017 Date of Revision: APR 28, 2023 Submission Control No: 269929 _APO-OLMESARTAN (Olmesartan medoxomil) _ _ _ _Page 2 of 33 _ RECENT MAJOR LABEL CHANGES 2 CONTRAINDICATIONS, Pregnancy and Breastfeeding 04/2023 7 WARNINGS AND PRECAUTIONS, 7.1 Special Populations, 7.1.1 Pregnant women 04/2023 TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES ............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS ................................................................................................................. 4 1.1 Pediatrics ............................................................................................................ 4 1.2 Geriatrics ............................................................................................................ 4 2 CONTRAINDICATIONS .................................................................................................... 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................... 5 4 DOSAGE AND ADMINISTRATION ................................................................................... 5 4.1 Dosing Considerations ........................................................................................ 5 4.2 Recommended Dose and Dosage Adjustment .................................................... 6 4.3 Reconstitution .................................................................................... Read the complete document